Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jane F Apperley

Showing results (1-10 of 195) with videos related to

Pageof 20
Sort By:
The Lancet. Oncology|December 7, 2007
Part II: management of resistance to imatinib in chronic myeloid leukaemiaJane F Apperley
The Lancet. Haematology|December 22, 2015
CML and tyrosine kinase inhibition: the hope becomes realityJane F Apperley
Lancet (London, England)|December 9, 2014
Chronic myeloid leukaemiaJane F Apperley
Hematology. American Society of Hematology. Education Program|November 25, 2006
Managing the patient with chronic myeloid leukemia through and after allogeneic stem cell transplantationJane F Apperley
Blood|July 27, 2013
TWIST it but don't spin itJane F Apperley
The Lancet. Oncology|November 3, 2007
Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemiaJane F Apperley
Nature Reviews. Clinical Oncology|June 3, 2010
Hematology. Imatinib--should we have more of a good thing?Jane F Apperley
Hematology. American Society of Hematology. Education Program|January 18, 2011
Long-term physiological side effects after allogeneic bone marrow transplantationMohamad Mohty, Jane F Apperley
Hematology. American Society of Hematology. Education Program|December 4, 2018
The argument for using imatinib in CMLSimone Claudiani, Jane F Apperley
Haematologica|December 1, 2022
Measurable residual disease in chronic myeloid leukemiaSusan Branford, Jane F Apperley
Pageof 20

Showing results (1-10 of 195) with videos related to

Sort By:
Pageof 20
The Lancet. Oncology|December 7, 2007
Part II: management of resistance to imatinib in chronic myeloid leukaemiaJane F Apperley
The Lancet. Haematology|December 22, 2015
CML and tyrosine kinase inhibition: the hope becomes realityJane F Apperley
Lancet (London, England)|December 9, 2014
Chronic myeloid leukaemiaJane F Apperley
Hematology. American Society of Hematology. Education Program|November 25, 2006
Managing the patient with chronic myeloid leukemia through and after allogeneic stem cell transplantationJane F Apperley
Blood|July 27, 2013
TWIST it but don't spin itJane F Apperley
The Lancet. Oncology|November 3, 2007
Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemiaJane F Apperley
Nature Reviews. Clinical Oncology|June 3, 2010
Hematology. Imatinib--should we have more of a good thing?Jane F Apperley
Hematology. American Society of Hematology. Education Program|January 18, 2011
Long-term physiological side effects after allogeneic bone marrow transplantationMohamad Mohty, Jane F Apperley
Hematology. American Society of Hematology. Education Program|December 4, 2018
The argument for using imatinib in CMLSimone Claudiani, Jane F Apperley
Haematologica|December 1, 2022
Measurable residual disease in chronic myeloid leukemiaSusan Branford, Jane F Apperley
Pageof 20